<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30916128</article-id><article-id pub-id-type="pmc">6436779</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0218</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Postoperative Atrial Fibrillation: Evaluation of its Economic Impact
on the Costs of Cardiac Surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6233-6912</contrib-id><name><surname>Hern&#x000e1;ndez-Leiva</surname><given-names>Edgar</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, MSc</role></contrib><contrib contrib-type="author"><name><surname>Alvarado</surname><given-names>Paula</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>RN</role></contrib><contrib contrib-type="author"><name><surname>Dennis</surname><given-names>Rodolfo Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD, MSc</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiology, Fundaci&#x000f3;n Cardioinfantil -
Instituto de Cardiolog&#x000ed;a, Bogot&#x000e1; DC, Colombia.</aff><aff id="aff2">
<label>2</label> Internal Medicine, Fundaci&#x000f3;n Cardioinfantil - Instituto de
Cardiolog&#x000ed;a, Bogot&#x000e1; DC, Colombia.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Edgar Hern&#x000e1;ndez-Leiva</bold>,
http://orcid.org/0000-0002-6233-6912, Fundaci&#x000f3;n Cardioinfantil -
Instituto de Cardiolog&#x000ed;a, Calle 163 A,n. 13B-60 - Bogot&#x000e1; DC,
Cundinamarca, Colombia. E-mail:
<email>edgarhernandez@cardioinfantil.org</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>34</volume><issue>2</issue><fpage>179</fpage><lpage>186</lpage><history><date date-type="received"><day>26</day><month>7</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The objective of this study was to calculate the direct costs of
postoperative atrial fibrillation (POAF) in a high-complexity cardiovascular
hospital.</p></sec><sec><title>Methods</title><p>We performed a cost analysis with a pairwise-matched design. Twenty-two
patients with POAF and 22 patients without this complication were included.
Pair-matching was performed (1:1) based on the following criteria: identical
type of surgery, similar EuroSCORE II values, and absence of any other
postoperative complication.</p></sec><sec><title>Results</title><p>The total hospital cost was significantly higher in the POAF group than in
the non-POAF group (US$ 10,880 [&#x000b1; 2,688] <italic>vs</italic>. US$
8,856 [&#x000b1; 1,782], respectively, for each patient;
<italic>P</italic>=0.005). This difference was attributable to postoperative
costs (US$ 3,103 [&#x000b1; 1,552] <italic>vs</italic>. US$ 1,238 [&#x000b1;
429]; <italic>P</italic>=0.0001) for patients with or without POAF,
respectively. The median postoperative lengths of stay were 9 (range 5-17)
and 5 (3-9) days for patients with and without POAF
(<italic>P</italic>=0.032), respectively. Preoperatively, no differences
were found in the EuroSCORE II values (median 1.7 <italic>vs</italic>. 1.6,
respectively; <italic>P</italic>=0.91) or direct costs (US$ 1,127
<italic>vs</italic>. US$ 1,063, respectively; <italic>P</italic>=0.56)
between POAF and non-POAF groups.</p></sec><sec><title>Conclusion</title><p>POAF generates a high economic burden in the overall costs of cardiac
surgery, and our results reveal the differential contribution of each of the
evaluated factors. This information, which was previously unavailable in
this setting, is essential for the development of more effective prevention
strategies.</p></sec></abstract><kwd-group><kwd>Atrial Fibrillation</kwd><kwd>Cardiac Surgery</kwd><kwd>Postoperative Care</kwd><kwd>Cost-of-Disease</kwd></kwd-group></article-meta></front><body><table-wrap id="t8" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="10%" span="1"/><col width="90%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Atrial fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cost-of-disease</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Confidence interval</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CVICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiovascular intensive
care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Odds ratio</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">POAF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Postoperative atrial
fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Standard deviation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">TAVR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Transcatheter aortic
valve replacement</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Postoperative atrial fibrillation (POAF) is the most common complication of cardiac
surgeries, with reported incidence rates between 10% and 65%, depending on the
cohort under study, definition, and detection method used<sup>[<xref rid="r1" ref-type="bibr">1</xref>-<xref rid="r2" ref-type="bibr">2</xref>]</sup>. This
complication is strongly associated with advanced age<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>; therefore, the progressive increase in the average
age of cardiac surgery patients in recent years requires a greater understanding of
the impact of POAF on clinical outcomes, the hospital resources consumed, and the
costs of medical care. Previous studies have shown that POAF continues to be an
important determinant of the duration of postoperative stay, use of resources, and
incidence of readmission<sup>[<xref rid="r4" ref-type="bibr">4</xref>-<xref rid="r7" ref-type="bibr">7</xref>]</sup>. However, the economic impact on
the costs of cardiac surgery has not been evaluated in the current setting. This
study seeks primarily to determine the direct medical costs of POAF and their
source, as well as evaluate if these results vary according to the type of
surgery.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This study was conducted in a 500-bed private tertiary care clinic with a
cardiovascular focus. All adult patients who underwent elective cardiac surgery
within a period of 23 months were included.</p><sec><title>Study Design</title><p>This study is a cost-of-disease (CD) analysis with a prevalent approach and it
was planned as a pairwise-matched study<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>, by matching patients with and without POAF (1:1)
concurrently. For identification purposes, patients were classified into one of
two groups according to whether they presented POAF: the POAF (+) group and the
POAF (-) group. This type of study design was considered necessary because costs
must be calculated against a counterfactual scenario in which the population
would have a hypothetical alternative occurrence of POAF but would be identical
in all other aspects<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>POAF was identified through continuous postoperative monitoring, which is already
conducted in the cardiovascular intensive care unit (CVICU), and later through
telemetry during the hospital stay. POAF was defined as the occurrence of any
episode of atrial fibrillation (AF) or flutter with a duration of 30 seconds or
longer (collectively called AF for this analysis) occurring postoperatively
until discharge and documented in an electrocardiographic trace<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>To study the independent effect of the variable of interest (POAF) on costs, the
influence of certain variables, such as surgery type, comorbidities, and the
absence of other postoperative complications, was controlled; these variables
were the matching criteria.</p><p>Of the two epidemiological perspectives that correspond to the interpretation of
CD studies, the prevalence-based approach was considered the most appropriate to
evaluate the actual economic burden of this health problem, given that it is the
main method chosen for the assessment of short-term acute conditions<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>.</p></sec><sec><title>Patients</title><p>All adult patients who underwent elective cardiac surgery comprising one of these
three procedures were included:</p><p>
<list list-type="bullet"><list-item><p>On-pump coronary bypass surgery.</p></list-item><list-item><p>Aortic valve replacement.</p></list-item><list-item><p>Mitral valve replacement or repair.</p></list-item></list>
</p><p>Patients were evaluated daily to record the occurrence of POAF. Those with a
history of any preoperative supraventricular arrhythmia were excluded.
Additionally, those subjected to percutaneous surgical procedures [transcatheter
aortic valve replacement (TAVR), aortic endoprosthesis, and other procedures)],
minimally invasive procedures, hybrid procedures, heart transplant, or surgeries
in which double procedures were performed were also excluded. These exclusions
made it challenging to appropriately match patients with certain procedures,
which resulted in uncertainty regarding the generalization of the results
obtained.</p><p>Given that statistical data of all patients during the postoperative period after
cardiac surgery are systematically recorded in the cardiovascular intensive care
unit (CVICU), POAF (-) patients were chosen as the first patients, after POAF
(+) patients, when they met the defined pairing criteria in the following
order:</p><p>
<list list-type="order"><list-item><p>No episode of POAF.</p></list-item><list-item><p>Identical type of surgery.</p></list-item><list-item><p>Similar EuroSCORE II values (as a global criterion of preoperative
morbidity and intraoperative risk), within a range of &#x000b1; 1.5%
with respect to the calculated point estimate</p></list-item><list-item><p>Absence of any other postoperative complication (*).</p></list-item></list>
</p><p>(*) Postoperative complications included clinical or laboratory procedures that,
in the opinion of the researchers, could have a significant impact on costs
(applies to both groups).</p></sec><sec><title>Study Objectives</title><p>
<list list-type="bullet"><list-item><p>To define the direct medical costs of POAF.</p></list-item><list-item><p>To determine the source of the costs (length of stay, medications,
laboratory procedures, diagnostic images, medical-surgical supplies,
physical therapy, and rehabilitation).</p></list-item><list-item><p>To evaluate if these results vary according to the type of surgery
(sensitivity analysis).</p></list-item></list>
</p></sec><sec><title>Outcomes</title><p>The main outcomes of interest evaluated were the direct medical costs
(intrahospital or 30 days postoperative costs, whichever occurred first), which
are described in <xref rid="t1" ref-type="table">Table 1</xref>. The study was
not designed to analyze associations among clinical outcomes. However, the
comorbidities that comprise the EuroSCORE II, the events of operative morbidity
and mortality, and durations of stay in the hospital and CVICU were
recorded.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Source of postoperative costs.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th style="border-bottom:hidden" align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) Monetary value US$ (mean and SD) </th><th align="center" rowspan="1" colspan="1">POAF (-) Monetary value US$ (mean and SD)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cost</td><td align="center" rowspan="1" colspan="1">3,103 (&#x000b1; 1.552)</td><td align="center" rowspan="1" colspan="1">1,238 (&#x000b1; 429)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay</td><td align="center" rowspan="1" colspan="1">1.451 (&#x000b1; 691)</td><td align="center" rowspan="1" colspan="1">553 (&#x000b1; 223)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Medicines</td><td align="center" rowspan="1" colspan="1">568 (&#x000b1; 354)</td><td align="center" rowspan="1" colspan="1">178 (&#x000b1; 113)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Laboratory procedures</td><td align="center" rowspan="1" colspan="1">365 (&#x000b1; 288)</td><td align="center" rowspan="1" colspan="1">166 (&#x000b1; 68)</td><td align="center" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" rowspan="1" colspan="1">Diagnostic imaging</td><td align="center" rowspan="1" colspan="1">240 (&#x000b1; 82)</td><td align="center" rowspan="1" colspan="1">136 (&#x000b1; 76)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Medical-surgical supplies</td><td align="center" rowspan="1" colspan="1">259 (&#x000b1; 291)</td><td align="center" rowspan="1" colspan="1">74 (&#x000b1; 42)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">Physical therapy and rehabilitation</td><td align="center" rowspan="1" colspan="1">174 (&#x000b1; 130)</td><td align="center" rowspan="1" colspan="1">117 (&#x000b1; 66)</td><td align="center" rowspan="1" colspan="1">0.38</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>Not all variables show a normal distribution; however, for clarity,
all data are shown as the means and standard deviations (SD).</p><p>All costs are expressed in US dollars using the exchange rate for
November 2017.</p><p>POAF=postoperative atrial fibrillation</p></fn></table-wrap-foot></table-wrap><p>The lengths of hospital and CVICU stays were quantified for each pair of patients
group, POAF (+) group <italic>vs</italic>. POAF (-) group, and the incremental
prolongation of the stay was calculated. The perspective of the third-party
payer was chosen for the cost analysis.</p><p>All the resources used were documented from the admission to the CVICU until the
hospital discharge or 30 postoperative days. The use of resources specifically
refers to DIRECT MEDICAL COSTS for the third-party payer, including the costs of
the stay, medications, supplies, tests, and procedures. The unit costs were
obtained from the billing system to reflect the hospital compensation for each
item. All financial information was adjusted to 2017 values considering current
rates updated at the time of analysis. The costs were obtained in Colombian
pesos and converted into US dollars (United States of America), based on the
exchange rate at the end of the analysis (November 2017).</p></sec><sec><title>Ethical Aspects</title><p>The research proposal was approved by the Institutional Research Ethics
Committee. The study was exempted from informed consent because it was an
anonymous analysis of data recorded in medical records or billing files and did
not affect the study plans or the patient's treatment.</p></sec><sec><title>Statistical Analysis</title><p>The analyses were performed with STATA 13.0 software (StataCorp LLC. TX 77845,
USA). Categorical variables are expressed as percentages, and continuous
variables are expressed as means and standard deviations (SD) or medians
[25<sup>th</sup> and 75<sup>th</sup> percentiles], according to their global
distribution.</p><p>The study was conducted according to the econometric approach described by
Changik Jo in a CD review<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>,
which compared the differences in mean costs supported by each of the two
cohorts to determine the incremental difference attributable to POAF. The two
groups were made comparable by one-to-one pairing to control potentially
confounding variables.</p><p>The first step in the statistical analysis was to define the characteristics of
distribution and variance of the variables under study. To compare the
differences in costs found between the groups, Student's or Welch's t-test was
used depending on the variance. For variables that did not meet the normality
criteria, the nonparametric Wilcoxon test was used. The resulting analyses were
considered statistically significant if the <italic>P</italic> values were fewer
than 0.05.</p></sec><sec><title>Calculation of the Sample Size</title><p>A priori, it was considered that the prolongation of the hospital stay would be
the most important factor in the increase of costs. According to the mean value
and standard deviation found in a previous global sample of patients and using
the formula for difference between means described by Dennis<sup>[<xref rid="r13" ref-type="bibr">13</xref>]</sup>, with a power of 0.8 and an
alpha level of 0.05 for a one-tailed test, a sample size of 16 patients in each
group was calculated. Accounting for the costs of other variables and after
adding an additional 10% for eventual losses of data necessary for the analyses,
a final sample of 44 patients was obtained (22 in each group). The researchers
considered that alternative methods of calculating the sample size could not be
applied to this study design.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>A total of 1,195 patients underwent cardiac surgical procedures during the 21-month
study period; see the flow chart in <xref ref-type="fig" rid="f1">Figure
1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Flowchart of the progress through the study phases.</p><p>AF=atrial fibrillation; CABG=coronary artery bypass grafting;
POAF=postoperative atrial fibrillation; TAVR=transcatheter aortic valve
replacement</p></caption><graphic xlink:href="rbccv-34-02-0179-g01"/></fig>
</p><sec><title>Characteristics of the Patients and Procedures</title><p>The study population consisted of 44 patients with an average age of 66.2
(&#x000b1; 8.4) years, 17 of whom were women (38.6%).</p><p><xref rid="t2" ref-type="table">Table 2</xref> shows that no significant
difference was found between the groups with respect to their baseline risk of
postoperative morbidity and mortality (estimated by the EuroSCORE II). Although
the patients' age is older in the POAF (+) group, this difference was not
significant. The types of surgery and number of patients are described in <xref rid="t3" ref-type="table">Table 3</xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Baseline characteristics.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+)</th><th align="center" rowspan="1" colspan="1">POAF (-)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (&#x000b1;SD)</td><td align="center" rowspan="1" colspan="1">67.9 (&#x000b1; 8.5)</td><td align="center" rowspan="1" colspan="1">64.4 (&#x000b1; 8.2)</td><td align="center" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" rowspan="1" colspan="1">Median EuroSCORE II (range)</td><td align="center" rowspan="1" colspan="1">1.73 (0.5-7.7)</td><td align="center" rowspan="1" colspan="1">1.65 (0.65-9)</td><td align="center" rowspan="1" colspan="1">0.91</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>The distribution by groups of each of the variables that composed the
EuroSCORE II (age, gender, renal function, extracardiac
arteriopathy, impaired mobility, previous cardiac surgery, chronic
lung disease, active endocarditis, critical preoperative state,
insulin-dependent diabetes mellitus, functional class, angina at
rest, left ventricular function, recent myocardial infarction,
pulmonary hypertension, emergency surgery, risk of intervention, and
surgery on the thoracic aorta).</p><p>POAF=postoperative atrial fibrillation; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Type of surgery.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="50%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) Number of patients</th><th align="center" rowspan="1" colspan="1">POAF (-) Number of patients</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Myocardial revascularization</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Aortic valve replacement</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Mitral valve replacement</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial revascularization + mitral valve
replacement</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial revascularization + mitral valve
repair</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>POAF=postoperative atrial fibrillation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Time of Stay and Costs</title><p><xref rid="t4" ref-type="table">Table 4</xref> shows why the total and
postoperative stay times were significantly prolonged in the subgroup with POAF
(in both the CVICU and the general hospital ward). <xref rid="t5" ref-type="table">Table 5</xref> shows that the total costs were significantly higher
in the POAF group, with an increase of approximately US$ 2,000 for each patient
presenting this outcome. It should be noted that the preoperative costs are not
different.</p><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Clinical outcomes.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="40%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/><col width="20%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) group</th><th align="center" rowspan="1" colspan="1">POAF (-) group</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total hospital stay in days (mean [SD])</td><td align="center" rowspan="1" colspan="1">13.1 (&#x000b1; 4.5)</td><td align="center" rowspan="1" colspan="1">9.5 (&#x000b1; 4.8)</td><td align="center" rowspan="1" colspan="1">0.008</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative CVICU stay in days (median [SD])</td><td align="center" rowspan="1" colspan="1">3.5 (1-11)</td><td align="center" rowspan="1" colspan="1">1 (1-3)</td><td align="center" rowspan="1" colspan="1">0.00001</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative stay on the hospitalization floor in
days (mean [SD])</td><td align="center" rowspan="1" colspan="1">4.9 (&#x000b1; 1.7)</td><td align="center" rowspan="1" colspan="1">3.8 (&#x000b1; 1.3)</td><td align="center" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Total postoperative stay in days (median
[range])</td><td align="center" rowspan="1" colspan="1">9 (5-17)</td><td align="center" rowspan="1" colspan="1">5 (3-9)</td><td align="center" rowspan="1" colspan="1">0.032</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of patients readmitted to CVICU
(median)</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>CVICU=cardiovascular intensive care unit; POAF=postoperative atrial
fibrillation; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="t5" orientation="portrait" position="float"><label>Table 5</label><caption><p>Costs.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) US$</th><th align="center" rowspan="1" colspan="1">POAF (-) US$</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Preoperative cost, median (range)</td><td align="center" rowspan="1" colspan="1">1,127 (0-3,796)</td><td align="center" rowspan="1" colspan="1">1,063 (0-3,534)</td><td align="center" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Postoperative cost, median (range)</td><td align="center" rowspan="1" colspan="1">2,596 (1,324-5,112)</td><td align="center" rowspan="1" colspan="1">1,225 (671-2,318)</td><td align="center" rowspan="1" colspan="1">0.00001</td></tr><tr><td align="left" rowspan="1" colspan="1">Total cost, mean (SD)</td><td align="center" rowspan="1" colspan="1">10,880 (&#x000b1; 2,688)</td><td align="center" rowspan="1" colspan="1">8,856 (&#x000b1; 1,782)</td><td align="center" rowspan="1" colspan="1">0.005</td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><p>All costs are expressed in US dollars using the exchange rate for
November 2017.</p><p>POAF=postoperative atrial fibrillation; SD=standard deviation</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Origin of Cost Overruns</title><p>Postoperative costs account for most of the differences in the total cost found
between the two groups. For purposes of the analysis, these postoperative costs
were discriminated into six groups according to their origin. <xref rid="t1" ref-type="table">Table 1</xref> and <xref ref-type="fig" rid="f2">Figure 2</xref> show that the main source of postoperative costs
corresponds to the hospital stay, but significant increases are also present in
the number of medications, laboratory procedures, diagnostic aids, and
medical-surgical supplies.</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Origin of postoperative costs.</p><p>POAF=postoperative atrial fibrillation</p></caption><graphic xlink:href="rbccv-34-02-0179-g02"/></fig>
</p></sec><sec><title>Sensitivity Analysis by Type of Surgery</title><p>The costs or their origin are not affected by the type of surgery. See <xref rid="t6" ref-type="table">Tables 6</xref> and <xref rid="t7" ref-type="table">7</xref>.</p><table-wrap id="t6" orientation="portrait" position="float"><label>Table 6</label><caption><p>Total postoperative cost and hospital stay in the subgroup of myocardial
revascularization patients.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) Monetary value US$ (mean and SD)</th><th align="center" rowspan="1" colspan="1">POAF (-) Monetary value US$ (mean and SD)</th><th align="center" rowspan="1" colspan="1"><italic>P </italic>value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cost</td><td align="center" rowspan="1" colspan="1">2,684 (&#x000b1; 1,163)</td><td align="center" rowspan="1" colspan="1">1,292 (&#x000b1; 372)</td><td align="center" rowspan="1" colspan="1">0.0003</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay</td><td align="center" rowspan="1" colspan="1">1,304 (&#x000b1; 627)</td><td align="center" rowspan="1" colspan="1">571 (&#x000b1; 233)</td><td align="center" rowspan="1" colspan="1">0.001</td></tr></tbody></table><table-wrap-foot><fn id="TFN6"><p>All costs are expressed in US dollars using the exchange rate for
November 2017.</p><p>POAF=postoperative atrial fibrillation; SD=standard deviation</p></fn></table-wrap-foot></table-wrap><table-wrap id="t7" orientation="portrait" position="float"><label>Table 7</label><caption><p>Total postoperative cost and hospital stay in the subgroup of patients
with other surgeries.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/><col width="25%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">POAF (+) Monetary value US$ (mean and SD)</th><th align="center" rowspan="1" colspan="1">POAF (-) Monetary value US$ (mean and SD)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total cost</td><td align="center" rowspan="1" colspan="1">3,523 (&#x000b1; 1.354)</td><td align="center" rowspan="1" colspan="1">1,184 (&#x000b1; 472)</td><td align="center" rowspan="1" colspan="1">0.000006</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital stay</td><td align="center" rowspan="1" colspan="1">1,598 (&#x000b1; 720)</td><td align="center" rowspan="1" colspan="1">535 (&#x000b1; 212)</td><td align="center" rowspan="1" colspan="1">0.0001</td></tr></tbody></table><table-wrap-foot><fn id="TFN7"><p>All costs are expressed in US dollars using the exchange rate for
November 2017.</p><p>POAF=postoperative atrial fibrillation; SD=standard deviation</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This is the first report on the impact of the costs of POAF after cardiac surgery in
Latin America. With the data obtained, we calculated an excess of total in-hospital
cost of approximately US$ 2,000 per patient. In absolute terms, the main component
of this cost is the increase in the length of hospital stay; however, the findings
likely underestimate the true cost of POAF because other potential costs exist. POAF
can be recurrent during the first weeks of the postoperative period<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, which implies that patients may
have consulted medical services for this arrhythmia and were readmitted to other
hospitals. Additionally, POAF has been associated with several postoperative
complications, including deep sternal wound infection<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, cerebrovascular events<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, gastrointestinal complications<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>, pneumonia<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>, and renal failure<sup>[<xref rid="r4" ref-type="bibr">4</xref>,<xref rid="r17" ref-type="bibr">17</xref>]</sup>; if causal
relationships with these complications were considered, the attributable costs would
be enormous.</p><p>Comparisons with the results of other studies are complicated by the local nature of
the costs and their variation over time. A study by Rostagno et al.<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup> evaluated the economic burden of
the POAF and found an extra cost of US$ 2,593 (original data published in euros, in
2010), of which approximately 50% was due to the excess cost of hospital stay. In a
publication by Hravnak et al.<sup>[<xref rid="r19" ref-type="bibr">19</xref>]</sup>
on patients undergoing coronary revascularization, those who developed POAF had
in-hospital costs that were US$ 6,356 higher than their counterparts without POAF
(2002). Aranky et al.<sup>[<xref rid="r20" ref-type="bibr">20</xref>]</sup>, in a
regression analysis adjusting for comorbidities and other postoperative
complications, reported that the number of additional days of hospitalization
attributable to POAF was 4.9, which corresponded to an extra US$ 10,055 to US$
11,500 of hospital charges per patient (1996). In their work, Doering LV et
al.<sup>[<xref rid="r21" ref-type="bibr">21</xref>]</sup> found that the
occurrence of postoperative arrhythmia was a variable that was independently
associated with higher costs, with an odds ratio (OR) of 3.5 (95% of confidence
interval [CI] 1.1-10.6).</p><p>In a similar study conducted by Mauldin et al.<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>, significant cardiac arrhythmia was demonstrated in 25% of
patients; the increase in the cost associated with arrhythmia compared to patients
without complications was approximately US$ 6,000 per patient. Similar results have
been reported by other authors, with additional costs attributable to POAF ranging
from US$ 5,000 to US$ 12,000 per patient<sup>[<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>.</p><p>To this date, studies have described the cost perspective of POAF on an individual
basis for each patient, but it is likely more important to analyze its overall
impact on a cardiac surgery program. Taylor et al.<sup>[<xref rid="r23" ref-type="bibr">23</xref>]</sup> reported that in the postoperative period of a
cardiac surgery, complications that may occur, when evaluated individually, generate
more costs than POAF; however, because POAF is the most frequent complication
(10-65% of all patients), its accumulated cost will exceed that of any other factor.
These authors examined the economic consequences of postoperative complications
associated after myocardial revascularization surgery. Respiratory failure and wound
infection of the sternum were the most costly complications, but they occurred in
only 3% and 0.4% of patients, respectively, while POAF was less expensive, but it
was the most common complication, occurring in 20% of patients. Assuming a similar
incidence of POAF in a cardiovascular hospital with a volume similar to ours
(approximately 600 adult surgeries each year), the overcosts could generate an
excess of US$ 600,000 annually.</p><p>The average cost overruns of POAF that we found in our study are lower than those
described in the literature; however, this is not only attributable to the
well-documented difference in the costs of cardiac surgery in industrialized and
developing countries<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>. A second
important factor is that to fulfill the objectives of the study, we have controlled
the influence of the main comorbidities that usually accompany POAF and the
different incidences of POAF according to the type of surgery by carefully pairing
the subjects by the EuroSCORE values and requiring the same type of surgery for each
pair to be compared. Few reports exist in the literature that have excluded patients
who presented any other complication prior or subsequent to the occurrence of POAF;
this measure allowed the actual and isolated costs to be refined, rather than
evaluating a conglomerate of conditions that are associated with the occurrence of
this postoperative complication. Finally, the increased in-hospital stay from 4 to 5
days in our series is consistent with that reported in older reports, of 7 to 10
days<sup>[<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>; we believe that this change is mainly explained
by the currently greater efficiency in the care processes.</p><p>The demonstration in our study that POAF is associated with an increase of more than
US$ 2,000 in total costs of care, US$ 900 in the in-hospital stay, approximately US$
400 in medications, US$ 300 in diagnostic tests and medical-surgical supplies, and
US$ 200 in laboratory procedures, is currently of high relevance because great
emphasis is placed on health care costs. These data also highlight an important
question related to the adherence to management guidelines because although
perioperative beta blockers are indicated as class I in POAF prevention<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup>, our database shows that a
proportion as high as 40% of patients referred for cardiac surgery do not receive
this medication.</p><p>One aspect to be emphasized in this research is the pairing criteria, which were
aimed at excluding confounding factors that could influence costs and therapeutic
practices. In the literature, emphasis is placed on the methodology used in cost
analysis due to the risk of biasing the results when not choosing the controls
appropriately.</p><p>This study has limitations. Firstly, the data were obtained from a single center,
which does not necessarily reflect the costs of all institutions, even in similar
settings. Additionally, the analyses were limited to the short term, and clinical
complications that frequently accompany POAF were not evaluated; however, the
inclusion of associated conditions would introduce "noise" into the analyses, making
it difficult to specify costs and to discriminate their origin.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>These results demonstrate that the occurrence of POAF is associated with a
significant increase in the use of hospital resources and direct costs. Our data
reflect the results of an institution focused on cardiovascular management and with
a high patient volume, providing a frame of reference for current and future
analyses related to the impact of this postoperative complication. The incidence of
POAF is increasing, and potential strategies for the prevention of POAF and the
appropriate selection of high-risk patients are still in development; therefore,
cost information is essential for the design of cost-effectiveness studies.</p><table-wrap id="t9" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">EHL</td><td align="left" valign="top" rowspan="1" colspan="1">Directed all aspects of the study,
including drafting the research proposal; presenting and defending
the protocol to the Institution's Ethics and Research Committees,
supervision of all the data collection of the study, review of the
study's CRFs and data base, and drafting of the final report;
approved the final manuscript</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PA</td><td align="left" valign="top" rowspan="1" colspan="1">Data collection and disseminated the
objectives and scope of the research in the institution; approved
the final manuscript</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">RJD</td><td align="left" valign="top" rowspan="1" colspan="1">Advised the methodological aspects of the
study, strengthening the epidemiological and statistical tools;
contributed to the drafting of the study's written reports; approved
the final manuscript</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Fundaci&#x000f3;n Cardioinfantil - Instituto de
Cardiolog&#x000ed;a, Bogot&#x000e0; DC, Colombia.</p></fn><fn fn-type="supported-by"><p><bold>Financial Support</bold></p><p>This study was funded by a grant from the Fundaci&#x000f3;n Cardioinfantil -
Instituto de Cardiolog&#x000ed;a. It is a high-complexity cardiac private
hospital of Bogot&#x000e1; DC, Colombia.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maisel</surname><given-names>WH</given-names></name><name><surname>Rawn</surname><given-names>JD</given-names></name><name><surname>Stevenson</surname><given-names>WG</given-names></name></person-group><article-title>Atrial fibrillation after cardiac surgery</article-title><source>Ann Intern Med</source><day>18</day><month>12</month><year>2001</year><volume>135</volume><issue>12</issue><fpage>1061</fpage><lpage>1073</lpage><pub-id pub-id-type="pmid">11747385</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shantsila</surname><given-names>E</given-names></name><name><surname>Watson</surname><given-names>T</given-names></name><name><surname>Lip</surname><given-names>GY</given-names></name></person-group><article-title>Atrial fibrillation post-cardiac surgery: changing
perspectives</article-title><source>Curr Med Res Opin</source><month>8</month><year>2006</year><volume>22</volume><issue>8</issue><fpage>1437</fpage><lpage>1441</lpage><pub-id pub-id-type="pmid">16870069</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathew</surname><given-names>JP</given-names></name><name><surname>Parks</surname><given-names>R</given-names></name><name><surname>Savino</surname><given-names>JS</given-names></name><name><surname>Friedman</surname><given-names>AS</given-names></name><name><surname>Koch</surname><given-names>C</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name><etal/></person-group><article-title>Atrial fibrillation following coronary artery bypass graft
surgery: predictors, outcomes, and resource utilization</article-title><person-group person-group-type="author"><collab>MultiCenter Study of Perioperative Ischemia Research Group</collab></person-group><source>JAMA</source><day>31</day><month>7</month><year>1996</year><volume>276</volume><issue>4</issue><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="pmid">8656542</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalavrouziotis</surname><given-names>D</given-names></name><name><surname>Buth</surname><given-names>KJ</given-names></name><name><surname>Ali</surname><given-names>IS</given-names></name></person-group><article-title>The impact of new-onset atrial fibrillation on in-hospital
mortality following cardiac surgery</article-title><source>Chest</source><month>3</month><year>2007</year><volume>131</volume><issue>3</issue><fpage>833</fpage><lpage>839</lpage><pub-id pub-id-type="doi">10.1378/chest.06-0735</pub-id><pub-id pub-id-type="pmid">17356100</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>MH</given-names></name><name><surname>Deeb</surname><given-names>GM</given-names></name><name><surname>Morady</surname><given-names>F</given-names></name><name><surname>Bruckman</surname><given-names>D</given-names></name><name><surname>Hallock</surname><given-names>LR</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><etal/></person-group><article-title>Effect of postoperative atrial fibrillation on length of stay
after cardiac surgery (The Postoperative Atrial Fibrillation in Cardiac
Surgery study [PACS (2)]</article-title><source>Am J Cardiol</source><day>01</day><month>4</month><year>2001</year><volume>87</volume><issue>7</issue><fpage>881</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">11274944</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lazar</surname><given-names>HL</given-names></name><name><surname>Fitzgerald</surname><given-names>C</given-names></name><name><surname>Gross</surname><given-names>S</given-names></name><name><surname>Heeren</surname><given-names>T</given-names></name><name><surname>Aldea</surname><given-names>GS</given-names></name><name><surname>Shemin</surname><given-names>RJ</given-names></name></person-group><article-title>Determinants of length of stay after coronary artery bypass graft
surgery</article-title><source>Circulation</source><day>01</day><month>11</month><year>1995</year><volume>92</volume><issue>9</issue><supplement>Suppl</supplement><fpage>II20</fpage><lpage>II24</lpage><pub-id pub-id-type="pmid">7586408</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname><given-names>D</given-names></name><name><surname>Kannel</surname><given-names>WB</given-names></name></person-group><article-title>Postoperative atrial fibrillation and mortality: do the risks
merit changes in clinical practice?</article-title><source>J Am Coll Cardiol</source><day>03</day><month>3</month><year>2004</year><volume>43</volume><issue>5</issue><fpage>749</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">14998611</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>Center for Diseases and Prevention (US)</collab><collab>Heart Disease &#x00026; Stroke Prevention</collab></person-group><source>Part II: Economic impact analysis. Cost of illness: the second of a
five-part series</source><comment>[Internet]</comment><year>2016</year><date-in-citation content-type="access-date">2019 Feb 6</date-in-citation><publisher-loc>Washington(DC)</publisher-loc><publisher-name>Department of Health and Human Services</publisher-name><size units="pages">49</size><comment>Available from: <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/dhdsp/programs/spha/economic_evaluation/docs/podcast_ii.pdf">https://www.cdc.gov/dhdsp/programs/spha/economic_evaluation/docs/podcast_ii.pdf</ext-link></comment></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Byford</surname><given-names>S</given-names></name><name><surname>Torgerson</surname><given-names>DJ</given-names></name><name><surname>Raftery</surname><given-names>J</given-names></name></person-group><article-title>Economic note: cost of illness studies</article-title><source>BMJ</source><day>13</day><month>5</month><year>2000</year><volume>320</volume><issue>7245</issue><fpage>1335</fpage><lpage>1335</lpage><pub-id pub-id-type="pmid">10807635</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosmidou</surname><given-names>I</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Serruys</surname><given-names>PW</given-names></name><name><surname>Gersh</surname><given-names>BJ</given-names></name><name><surname>Puskas</surname><given-names>JD</given-names></name><etal/></person-group><article-title>New-Onset Atrial Fibrillation After PCI or CABG for Left Main
Disease: The EXCEL Trial</article-title><source>J Am Coll Cardiol</source><day>20</day><month>2</month><year>2018</year><volume>71</volume><issue>7</issue><fpage>739</fpage><lpage>748</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2017.12.012</pub-id><pub-id pub-id-type="pmid">29447735</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larg</surname><given-names>A</given-names></name><name><surname>Moss</surname><given-names>JR</given-names></name></person-group><article-title>Cost-of-illness studies: a guide to critical
evaluation</article-title><source>Pharmacoeconomics</source><month>8</month><year>2011</year><volume>29</volume><issue>8</issue><fpage>653</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.2165/11588380-000000000-00000</pub-id><pub-id pub-id-type="pmid">21604822</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>C</given-names></name></person-group><article-title>Cost-of-illness studies: concepts, scopes, and
methods</article-title><source>Clin Mol Hepatol</source><month>12</month><year>2014</year><volume>20</volume><issue>4</issue><fpage>327</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.3350/cmh.2014.20.4.327</pub-id><pub-id pub-id-type="pmid">25548737</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>R</given-names></name></person-group><article-title>C&#x000f3;mo estimar el tama&#x000f1;o de la muestra en
investigaciones con humanos</article-title><source>Acta Med Colomb</source><year>1989</year><volume>14</volume><issue>2</issue><fpage>92</fpage><lpage>99</lpage></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambrosetti</surname><given-names>M</given-names></name><name><surname>Tramarin</surname><given-names>R</given-names></name><name><surname>Griffo</surname><given-names>R</given-names></name><name><surname>De Feo</surname><given-names>S</given-names></name><name><surname>Fattirolli</surname><given-names>F</given-names></name><name><surname>Vestri</surname><given-names>A</given-names></name><etal/></person-group><article-title>Late postoperative atrial fibrillation after cardiac surgery: a
national survey within the cardiac rehabilitation setting</article-title><source>J Cardiovasc Med (Hagerstown)</source><month>6</month><year>2011</year><volume>12</volume><issue>6</issue><fpage>390</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.2459/JCM.0b013e328346a6d3</pub-id><pub-id pub-id-type="pmid">21508846</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almassi</surname><given-names>GH</given-names></name><name><surname>Schowalter</surname><given-names>T</given-names></name><name><surname>Nicolosi</surname><given-names>AC</given-names></name><name><surname>Aggarwal</surname><given-names>A</given-names></name><name><surname>Moritz</surname><given-names>TE</given-names></name><name><surname>Henderson</surname><given-names>WG</given-names></name><name><surname>Tarazi</surname><given-names>R</given-names></name><name><surname>Shroyer</surname><given-names>AL</given-names></name><name><surname>Sethi</surname><given-names>GK</given-names></name><name><surname>Grover</surname><given-names>FL</given-names></name><name><surname>Hammermeister</surname><given-names>KE</given-names></name></person-group><article-title>Atrial fibrillation after cardiac surgery: a major morbid
event?</article-title><source>Ann Surg</source><month>10</month><year>1997</year><volume>226</volume><issue>4</issue><fpage>501</fpage><lpage>511</lpage><pub-id pub-id-type="pmid">9351718</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>B</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Brandt</surname><given-names>J</given-names></name><name><surname>H&#x000f6;glund</surname><given-names>P</given-names></name><name><surname>Andersson</surname><given-names>R</given-names></name></person-group><article-title>Gastrointestinal complications after cardiac
surgery</article-title><source>Br J Surg</source><month>3</month><year>2005</year><volume>92</volume><issue>3</issue><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="pmid">15672438</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albahrani</surname><given-names>MJ</given-names></name><name><surname>Swaminathan</surname><given-names>M</given-names></name><name><surname>Phillips-Bute</surname><given-names>B</given-names></name><name><surname>Smith</surname><given-names>PK</given-names></name><name><surname>Newman</surname><given-names>MF</given-names></name><name><surname>Mathew</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Postcardiac surgery complications: association of acute renal
dysfunction and atrial fibrillation</article-title><source>Anesth Analg</source><month>3</month><year>2003</year><volume>96</volume><issue>3</issue><fpage>637</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">12598236</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rostagno</surname><given-names>C</given-names></name><name><surname>La Meir</surname><given-names>M</given-names></name><name><surname>Gelsomino</surname><given-names>S</given-names></name><name><surname>Ghilli</surname><given-names>L</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Carone</surname><given-names>E</given-names></name><etal/></person-group><article-title>Atrial fibrillation after cardiac surgery: incidence, risk
factors, and economic burden</article-title><source>J Cardiothorac Vasc Anesth</source><month>12</month><year>2010</year><volume>24</volume><issue>6</issue><fpage>952</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1053/j.jvca.2010.03.009</pub-id><pub-id pub-id-type="pmid">20570180</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hravnak</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>LA</given-names></name><name><surname>Saul</surname><given-names>MI</given-names></name><name><surname>Zullo</surname><given-names>TG</given-names></name><name><surname>Whitman</surname><given-names>GR</given-names></name></person-group><article-title>Resource utilization related to atrial fibrillation after
coronary artery bypass grafting</article-title><source>Am J Crit Care</source><month>5</month><year>2002</year><volume>11</volume><issue>3</issue><fpage>228</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">12022486</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aranki</surname><given-names>SF</given-names></name><name><surname>Shaw</surname><given-names>DP</given-names></name><name><surname>Adams</surname><given-names>DH</given-names></name><name><surname>Rizzo</surname><given-names>RJ</given-names></name><name><surname>Couper</surname><given-names>GS</given-names></name><name><surname>VanderVliet</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictors of atrial fibrillation after coronary artery surgery.
Current trends and impact on hospital resources</article-title><source>Circulation</source><day>01</day><month>8</month><year>1996</year><volume>94</volume><issue>3</issue><fpage>390</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">8759081</pub-id></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doering</surname><given-names>LV</given-names></name><name><surname>Esmailian</surname><given-names>F</given-names></name><name><surname>Laks</surname><given-names>H</given-names></name></person-group><article-title>Perioperative predictors of ICU and hospital costs in coronary
artery bypass graft surgery</article-title><source>Chest</source><month>9</month><year>2000</year><volume>118</volume><issue>3</issue><fpage>736</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">10988196</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mauldin</surname><given-names>PD</given-names></name><name><surname>Weintraub</surname><given-names>WS</given-names></name><name><surname>Becker</surname><given-names>ER</given-names></name></person-group><article-title>Predicting hospital costs for first-time coronary artery bypass
grafting from preoperative and postoperative variables</article-title><source>Am J Cardiol</source><day>15</day><month>10</month><year>1994</year><volume>74</volume><issue>8</issue><fpage>772</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">7942547</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>GJ</given-names></name><name><surname>Mikell</surname><given-names>FL</given-names></name><name><surname>Moses</surname><given-names>HW</given-names></name><name><surname>Dove</surname><given-names>JT</given-names></name><name><surname>Katholi</surname><given-names>RE</given-names></name><name><surname>Malik</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Determinants of hospital charges for coronary artery bypass
surgery: the economic consequences of postoperative
complications</article-title><source>Am J Cardiol</source><day>01</day><month>2</month><year>1990</year><volume>65</volume><issue>5</issue><fpage>309</fpage><lpage>313</lpage><pub-id pub-id-type="pmid">2105627</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname><given-names>JP</given-names></name><name><surname>Horowitz</surname><given-names>MD</given-names></name><name><surname>Mavroudis</surname><given-names>C</given-names></name><name><surname>Siegel</surname><given-names>A</given-names></name><name><surname>Sade</surname><given-names>RM</given-names></name></person-group><article-title>Surgical tourism: the role of cardiothoracic surgery societies in
evaluating international surgery centers</article-title><source>Ann Thorac Surg</source><month>7</month><year>2013</year><volume>96</volume><issue>1</issue><fpage>8</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2013.02.058</pub-id><pub-id pub-id-type="pmid">23816068</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirchhof</surname><given-names>P</given-names></name><name><surname>Benussi</surname><given-names>S</given-names></name><name><surname>Kotecha</surname><given-names>D</given-names></name><name><surname>Ahlsson</surname><given-names>A</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Casadei</surname><given-names>B</given-names></name><etal/></person-group><article-title>2016 ESC Guideline for the management of atrial fibrillation
developed in collaboration with EACTS</article-title><source>Eur Heart J</source><year>2016</year><volume>38</volume><issue>7</issue><fpage>2893</fpage><lpage>2862</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehx039</pub-id></element-citation></ref></ref-list></back></article>